Source: http://www4.law.cornell.edu/uscode/text/21/812?quicktabs_8=4
Timestamp: 2013-12-11 06:30:27
Document Index: 77174049

Matched Legal Cases: ['§ 812', '§ 812', '§ 812', 'art 1308', '§ 202', '§ 103', '§ 507', '§ 1867', '§ 84', '§ 1902', '§ 507', '§ 509', '§ 2', '§ 8122012112']

21 USC § 812 - Schedules of controlled substances | Title 21 - Food and Drugs | U.S. Code | LII / Legal Information Institute
USC › Title 21 › Chapter 13 › Subchapter I › Part B › § 812	prevnext
21 USC § 812 - Schedules of controlled substances
Establishment There are established five schedules of controlled substances, to be known as schedules I, II, III, IV, and V. Such schedules shall initially consist of the substances listed in this section. The schedules established by this section shall be updated and republished on a semiannual basis during the two-year period beginning one year after October 27, 1970, and shall be updated and republished on an annual basis thereafter.
Placement on schedules; findings required Except where control is required by United States obligations under an international treaty, convention, or protocol, in effect on October 27, 1970, and except in the case of an immediate precursor, a drug or other substance may not be placed in any schedule unless the findings required for such schedule are made with respect to such drug or other substance. The findings required for each of the schedules are as follows:
Schedule I.— (A)
Schedule II.— (A)
Schedule III.— (A)
Schedule IV.— (A)
Schedule V.— (A)
Initial schedules of controlled substances Schedules I, II, III, IV, and V shall, unless and until amended [1]
pursuant to section 811 of this title, consist of the following drugs or other substances, by whatever official name, common or usual name, chemical name, or brand name designated:
Alphacetylmathadol.
Dextrorphan.
Propheptazine.
Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Codeine methylbromide.
Codeine-N-Oxide.
Cyprenorphine.
Methylhydromorphine.
Morphine methylbromide.
Morphine methylsulfonate.
Morphine-N-Oxide.
3,4-methylenedioxy amphetamine.
5-methoxy-3,4-methylenedioxy amphetamine.
3,4,5-trimethoxy amphetamine.
Diethyltryptamine.
4-methyl-2,5-diamethoxyamphetamine.
N-ethyl-3-piperidyl benzilate.
N-methyl-3-piperidyl benzilate.
Psilocyn.
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E).
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D).
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C).
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I).
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2).
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4).
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H).
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N).
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P).
Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
The term “cannabimimetic agents” means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:
5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP–47,497);
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog);
1-pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678);
1-butyl-3-(1-naphthoyl)indole (JWH–073);
1-hexyl-3-(1-naphthoyl)indole (JWH–019);
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200);
1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250);
1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081);
1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122);
1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398);
1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19 and RCS–4);
1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8); and
1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–203).
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate.
Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (1), except that these substances shall not include the isoquinoline alkaloids of opium.
coca [3]
leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric isomers, and salts of isomers; ecgonine, its derivatives, their salts, isomers, and salts of isomers; or any compound, mixture, or preparation which contains any quantity of any of the substances referred to in this paragraph.
Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane.
Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid.
Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine.
Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate.
Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid.
Chorhexadol.
Lysergic acid amide.
Methyprylon.
Sulfondiethylmethane.
Sulfonethylmethane.
Sulfonmethane.
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Chloral betaine.
Methohexital.
Petrichloral.
Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
Revised schedules are published in the Code of Federal Regulations, Part 1308 of Title 21, Food and Drugs.
So in original. Probably should be “Alphacetylmethadol.”
(Pub. L. 91–513, title II, § 202,Oct. 27, 1970, 84 Stat. 1247; Pub. L. 95–633, title I, § 103,Nov. 10, 1978, 92 Stat. 3772; Pub. L. 98–473, title II, §§ 507(c), 509
(b),Oct. 12, 1984, 98 Stat. 2071, 2072; Pub. L. 99–570, title I, § 1867,Oct. 27, 1986, 100 Stat. 3207–55; Pub. L. 99–646, § 84,Nov. 10, 1986, 100 Stat. 3619; Pub. L. 101–647, title XIX, § 1902(a),Nov. 29, 1990, 104 Stat. 4851.)
1990—Subsec. (c). Pub. L. 101–647added item (e) at end of schedule III.
1986—Subsec. (c). Pub. L. 99–646amended schedule II(a)(4) generally. Prior to amendment, schedule II(a)(4) read as follows: “Coca leaves (except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed); cocaine, its salts, optical and geometric isomers, and salts of isomers; and ecgonine, its derivatives, their salts, isomers, and salts of isomers.”
Pub. L. 99–570amended schedule II(a)(4) generally. Prior to amendment, schedule II(a)(4) read as follows: “Coca leaves and any salt, compound, derivative, or preparation of coca leaves (including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.”
1984—Subsec. (c). Pub. L. 98–473, § 507(c), in schedule II(a)(4) added applicability to cocaine and ecgonine and their salts, isomers, etc.
Subsec. (d). Pub. L. 98–473, § 509(b), struck out subsec. (d) which related to authority of Attorney General to except stimulants or depressants containing active medicinal ingredients.
1978—Subsec. (d)(3). Pub. L. 95–633added cl. (3).
Amendment by Pub. L. 101–647effective 90 days after Nov. 29, 1990, see section 1902(d) ofPub. L. 101–647, set out as a note under section 802 of this title.
Pub. L. 106–172, §§ 2, 3
(a),Feb. 18, 2000, 114 Stat. 7, 8, provided that:
“(2) A behavioral depressant and a hypnotic, gamma hydroxybutyric acid (‘GHB’) is being used in conjunction with alcohol and other drugs with detrimental effects in an increasing number of cases. It is difficult to isolate the impact of such drug’s ingestion since it is so typically taken with an ever-changing array of other drugs and especially alcohol which potentiates its impact.
“(1) In general.—The Congress finds that the abuse of illicit gamma hydroxybutyric acid is an imminent hazard to the public safety. Accordingly, the Attorney General, notwithstanding sections 201(a), 201(b), 201(c), and 202 of the Controlled Substances Act [21 U.S.C. 811
(a)–(c), 812], shall issue, not later than 60 days after the date of the enactment of this Act [Feb. 18, 2000], a final order that schedules such drug (together with its salts, isomers, and salts of isomers) in the same schedule under section 202(c) of the Controlled Substances Act as would apply to a scheduling of a substance by the Attorney General under section 201(h)(1) of such Act (relating to imminent hazards to the public safety), except as follows:
“(A) For purposes of any requirements that relate to the physical security of registered manufacturers and registered distributors, the final order shall treat such drug, when the drug is manufactured, distributed, or possessed in accordance with an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355
(i)] (whether the exemption involved is authorized before, on, or after the date of the enactment of this Act [Feb. 18, 2000]), as being in the same schedule as that recommended by the Secretary of Health and Human Services for the drug when the drug is the subject of an authorized investigational new drug application (relating to such section 505
(i)). The recommendation referred to in the preceding sentence is contained in the first paragraph of the letter transmitted on May 19, 1999, by such Secretary (acting through the Assistant Secretary for Health) to the Attorney General (acting through the Deputy Administrator of the Drug Enforcement Administration), which letter was in response to the letter transmitted by the Attorney General (acting through such Deputy Administrator) on September 16, 1997. In publishing the final order in the Federal Register, the Attorney General shall publish a copy of the letter that was transmitted by the Secretary of Health and Human Services.
“(2) Failure to issue order.—If the final order is not issued within the period specified in paragraph (1), gamma hydroxybutyric acid (together with its salts, isomers, and salts of isomers) is deemed to be scheduled under section 202(c) of the Controlled Substances Act [21 U.S.C. 812
(c)] in accordance with the policies described in paragraph (1), as if the Attorney General had issued a final order in accordance with such paragraph.”
Section 102(c) ofPub. L. 95–633provided that: “For the purpose of carrying out the minimum United States obligations under paragraph 7 of article 2 of the Convention on Psychotropic Substances, signed at Vienna, Austria, on February 21, 1971, with respect to pipradrol and SPA (also known as (-)-1-dimethylamino-1,2-diphenylethane), the Attorney General shall by order, made without regard to sections 201 and 202 of the Controlled Substances Act [this section and section 811 of this title], place such drugs in schedule IV of such Act [see subsec. (c) of this section].”
Provision of section 102(c) ofPub. L. 95–633, set out above, effective on the date the Convention on Psychotropic Substances enters into force in the United States [July 15, 1980], see section 112 ofPub. L. 95–633, set out as an Effective Date note under section 801a of this title.
21 USCDescription of ChangeSession YearPublic LawStatutes at Large § 8122012112-144 [Sec.] 1152126 Stat. 1130 This is a list of parts within the Code of Federal Regulations for which this US Code section provides rulemaking authority.This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.21 CFR - Food and Drugs21 CFR 1308 - SCHEDULES OF CONTROLLED SUBSTANCES21 CFR 1316 - ADMINISTRATIVE FUNCTIONS, PRACTICES, AND PROCEDURES
Search US Code: Law about... Articles from WexDownload the PDF (8 pgs) Title 21 USC, RSS Feed